Trended surveillance of HIV
epidemiology in MSM across the
EU5
Samantha Fernando PhD
METHOD:
• Syndicated HIV Therapy Monitor and Scope studies
• Running since 1996
• Collect data from 230 physicians across the EU5
• Physicians report on patients seen within each study period
© 2012 Ipsos
BACKGROUND:
• Examine how MSM antiretroviral treatment adoption has evolved
• Identify MSM population-specific differences relative to all HIV patients
© 2014 Ipsos. All rights reserved. Contains Ipsos' Confidential and Proprietary information
and may not be disclosed or reproduced without the prior written consent of Ipsos.
1
RESULTS: HIV guideline changes in the EU5
Diagnosed patients not currently
receiving ARV therapy-never been treated
/naive
Average CD4 count at initiation
400.0
350.0
30
300.0
CD4 count/mm3
25
15
NICE PH34 guideline
change
10
200.0
150.0
European AIDS Clinical
Society guideline
change
WHO
guideline
change
Source: Ipsos HIV Monitor EU5
© 2012 Ipsos
2014 Q1
2013 Q3
2013 Q1
2012 Q3
2012 Q1
2011 Q3
2011 Q1
0.0
2010 Q3
0
2010 Q1
50.0
2009 Q3
5
2009 Q1
2009 Q2
2009 Q3
2009 Q4
2010 Q1
2010 Q2
2010 Q3
2010 Q4
2011 Q1
2011 Q2
2011 Q3
2011 Q4
2012 Q1
2012 Q2
2012 Q3
2012 Q4
2013 Q1
2013 Q2
2013 Q3
2013 Q4
2014 Q1
100.0
2009 Q1
% patients
20
250.0
Source: Ipsos HIV Scope EU5
2
CONCLUSIONS: A marked shift in MSM
treatment adoption
Length of time between diagnosis and initiation of
first line therapy
Country specific 14Q1 MSM data
• MSM relative to all patients in the 5EU are more responsive to starting
treatment
• Earlier capture and treatment initiation is imperative to suppress viral load,
increasing future treatment success and controlling HIV progression amongst
this high-risk group
© 2012 Ipsos
Source: Ipsos HIV Scope EU5
3